Pharmaceutical Preparation Manufacturing (United States)

NAICS 2022 code 325412 — the factories that turn drug ingredients into the finished medicines patients actually take: tablets, capsules, injectables, ointments, solutions, and patches.

---

1. Overview

This is the business of manufacturing finished pharmaceutical products — the pills and shots on pharmacy shelves — as opposed to discovering the chemistry or selling the drug at retail. In practice the code captures the core manufacturing arm of the branded-drug and generic-drug industries.

Why an investor cares: medicines are a large, defensive, and fast-growing part of the economy. U.S. prescription-drug spending reached about $805.9 billion in 2024, up 10.2% year over year — the fastest growth since the COVID-19 vaccine year [1]. (The retail subset alone was $467.0 billion, up 7.9% [2].) CMS projects retail prescription drugs to be the fastest-growing major health-spending category over 2025–2034, at an average 5.7% annual rate [2]. Demand is driven by aging, chronic disease, and a wave of blockbuster obesity and diabetes drugs, and it is relatively insensitive to recessions. The trade-off is unusual risk concentration: a single drug can be worth tens of billions a year, and a single patent expiration or regulatory decision can erase that value.

There are two distinct ways in. Public-market investors can own large, profitable, dividend-paying drugmakers, high-growth names, or sector funds on U.S. exchanges. Private investors back the earlier, riskier layers — venture-funded clinical-stage biotech, private-equity ownership of generic and specialty manufacturers, contract-manufacturing platforms, and drug-royalty deals. The economics of these two layers are almost opposite, and both live inside this one industry code.

---

2. What it is and how it's structured

Scope. NAICS 325412 (North American Industry Classification System — the U.S. government's standard for grouping businesses) covers establishments primarily making pharmaceutical preparations and in-vivo diagnostic substances for internal or external use, in finished dose forms — ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions. Products include prescription and nonprescription medicines, sterile injectables and IV solutions, contrast media, veterinary medicines, and certain compounded dietary or herbal supplements [3][4].

What it deliberately excludes — these sit in adjacent codes:

• NAICS 325411, Medicinal and Botanical Manufacturing — uncompounded active ingredients and bulk medicinal chemicals (the raw drug substance) [3].
• NAICS 325414, Biological Product (except Diagnostic) Manufacturing — vaccines, blood fractions, and most large-molecule biologics of plant/animal origin [3].
• NAICS 325413, In-Vitro Diagnostic Substance Manufacturing — lab test reagents used outside the body [3].

So 325412 is specifically the "formulate and fill" step for conventional (mostly chemical, small-molecule) medicines. Note a real-world blur: many companies span these codes, and the classification predates the biologics boom, so some antibody and cell-therapy work is captured only partially here.

How manufacturing works. Operationally, manufacturers procure APIs, excipients, sterile water, packaging, containers, and drug-delivery components; formulate them into a dosage form; validate and control the process; test and release each batch; package and serialize the finished product; and maintain stability, deviation, and complaint records. Solid-dose plants typically blend, granulate, compress or encapsulate, coat, and package. Sterile operations add filtration or sterilization, cleanrooms, aseptic filling, and much tighter environmental controls. FDA's current good manufacturing practice (CGMP) rules prescribe minimum requirements for the methods, facilities, and controls used in processing and packing drugs [5].

A company need not perform all these steps itself. Product owners routinely outsource API production, formulation, fill-finish, testing, device assembly, and packaging to contract development and manufacturing organizations (CDMOs). FDA expects the owner and contractor to define their respective CGMP responsibilities in a quality agreement; outsourcing does not eliminate the product owner's regulatory responsibility [6]. Batch production remains common, but FDA's emerging-technology program also covers continuous manufacturing, process analytical technology, distributed manufacturing, three-dimensional printing, and artificial intelligence [7].

Ownership mix. This is the opposite of a fragmented, mom-and-pop industry. It is dominated by large, publicly traded multinationals — some U.S.-headquartered (Pfizer, Merck, Eli Lilly, Johnson & Johnson, AbbVie), some foreign (Novartis, AstraZeneca, Novo Nordisk, Roche). Beneath them sit a long tail of privately held or venture-backed clinical-stage biotech firms (no products yet, funded by equity), generic and specialty manufacturers (many foreign-owned), and contract development and manufacturing organizations (CDMOs) that make drugs for hire. Government and non-profit production is minimal.

---

3. How big it is

Our federal figures describe the U.S. manufacturing footprint of the industry — the plants located on U.S. soil — not the global revenue of the companies that own them.

Establishment size distribution. The physical-location distribution is long-tailed: 369 establishments had fewer than five employees, while 53 had 500–999 employees and 19 had at least 1,000 [8]. Small sites are numerous, but the industry also contains a limited group of very large plants.

How to read the concentration numbers. The four largest firms ship about 40% of U.S. output and the top 50 ship 81% [9] — a top-heavy industry. Yet the HHI (a standard concentration score where antitrust regulators treat anything under 1,500 as "unconcentrated") is only 557 [9], because output is spread across enough distinct firms that no single one dominates manufacturing nationally. Concentration is far higher within any one disease or drug, where a patented product can be a near-monopoly.

The measurement caveat (why the figures look small). The $165.8 billion of domestic sales/shipments [10] is far below the ~$806 billion Americans spend on prescriptions [1] for three reasons: (a) receipts are valued at the factory gate, not the pharmacy counter — retail prices include huge wholesale, pharmacy, and middleman markups; (b) a large share of medicines sold here are made abroad and imported; and (c) the code counts manufacturing plants only. A drug company's scientists (research NAICS 5417), corporate headquarters (NAICS 5511), and sales forces sit in other codes. So the 170,029 manufacturing employees [8] sharply understate the sector's true U.S. footprint: the broader biopharmaceutical industry directly employs over 1 million Americans [13]. When you read "170,000 jobs," read it as factory jobs, not the whole industry.

---

4. The investable universe

Unlike many industries in this series, this one has an unusually deep and liquid set of public plays — most of the household-name drugmakers trade on U.S. exchanges, either directly or as American Depositary Receipts (ADRs — foreign shares that trade in dollars in New York). Figures are approximate 2025 global revenue; a company's U.S.-based manufacturing (what 325412 measures) is only a slice of it.

Large branded drugmakers (U.S.-listed)

Major foreign drugmakers with big U.S. operations (U.S.-listed ADRs)

Generics, specialty, and contract manufacturers

Diversified exposure. A sector fund such as the SPDR S&P Pharmaceuticals ETF (XPH) supplies basket exposure across many names, though it follows an equity-industry index, not NAICS 325412 domestic output [21].

Takeaway for allocators. The branded names are mature, cash-generative businesses that pay dividends and buy back stock; the risk is specific (patents, pipeline, pricing), not economic-cycle risk. The generic and CDMO names are lower-margin, volume-driven, and increasingly consolidated. The riskiest and potentially highest-return layer — clinical-stage biotech with no revenue — is mostly reached through small-cap stocks, biotech funds, or private venture capital.

---

5. How the money works

Drugmakers make money in a way unlike almost any other manufacturer, and the mechanics differ sharply between branded and generic firms.

The branded (patent) model. A company spends heavily and for years to discover a drug, prove it works, and win approval — the biopharma industry spent roughly $96 billion on R&D in 2023 [13], most candidates fail, and bringing one drug to market can cost well over a billion dollars. The payoff is a patent-protected monopoly: for a period of years the company is the only legal seller and can price accordingly. During exclusivity, gross margins on a successful branded drug are very high — commonly 70–90% — because the marginal cost of a pill is trivial next to its price. Eli Lilly reported 2025 revenue of $65.2 billion and cost of sales of $11.1 billion, implying a consolidated gross margin of roughly 83% for its innovation-led global pharmaceutical business [22]. Revenue is extremely concentrated in a handful of "blockbusters" (drugs earning over $1 billion a year); a single product can be a third of a company's sales.

The key metrics to watch are therefore drug-level, not plant-level:

• Pipeline and approvals — how many late-stage candidates could replace today's earners.
• Loss of exclusivity (LOE) dates — when a blockbuster's patents expire and copycats can enter.
• Net vs. list price — the "gross-to-net" gap. Headline list prices are heavily discounted through rebates to pharmacy benefit managers (PBMs — the middlemen who negotiate drug coverage for insurers), plus mandatory Medicaid and 340B discounts. What the maker actually collects can be far below the sticker.

The patent cliff. When exclusivity ends, generic or biosimilar competitors launch, and for a small-molecule drug price and volume can collapse 80–90% within a year. Lilly describes loss of effective protection as frequently causing a rapid and severe revenue decline for the affected product [22]. Replacing that lost revenue is the central strategic problem of the industry (see Sections 8–9).

The generic model — the mirror image. Generic makers copy off-patent drugs and compete on price. There is no monopoly and no premium: margins are thin. FDA reports that one generic competitor has been associated with a 30% price reduction and five competitors with price declines approaching 85% [23]. Generic leader Teva ran a gross margin near 49.5% in early 2026 [24], while Viatris, with greater exposure to mature brands and purchase-accounting amortization, reported a 2025 GAAP gross margin of 35% [25] — both well below the 70–80%+ of branded peers. Success is about scale, manufacturing efficiency, and being first to launch after a patent lapses. It is a commodity business with commodity economics.

The CDMO model. Contract manufacturers make drugs for other companies for a fee. They earn on capacity utilization and long-term supply contracts rather than on owning any drug — closer to an industrial-services business.

Principal manufacturing cost drivers are APIs and excipients; sterile or high-containment processing; delivery devices and packaging; quality-control laboratories; validation and regulatory maintenance; skilled production and quality labor; utilities; depreciation; rejected batches; inventory write-offs; and idle or underutilized capacity. The industry carried $35.5 billion of year-end inventories in 2023 [11], underscoring the working capital tied up in raw material, work-in-process, and finished product stocks.

How owners get paid. Mature branded and generic firms return cash through dividends and buybacks. Clinical-stage biotech pays nothing and burns cash, funded by issuing equity; the return comes if a drug succeeds and the company is acquired or its product reaches market. Royalty investors buy a slice of a drug's future sales for upfront cash. These are three genuinely different investments living under one industry label.

---

6. What drives demand

• Aging and chronic disease. Older populations consume far more medicine; diabetes, cancer, cardiovascular, and autoimmune disease all rise with age and are the industry's largest categories. Census's middle population projection has the share aged 65 and older surpassing the share under 18 in 2029 [26].
• The obesity/GLP-1 wave. GLP-1 drugs (glucagon-like peptide-1 receptor agonists — the diabetes/weight-loss class including semaglutide and tirzepatide) are the single biggest growth engine right now, accounting for roughly 29% of all 2024 U.S. drug-spending growth [1]. Semaglutide and tirzepatide are now the two top-selling drugs in the country [1], and the addressable population is still expanding.
• Innovation and label expansion. New launches and approvals of existing drugs for additional diseases open large new patient pools; oncology alone is expected to see over 100 launches and expansions through the late 2020s [27].
• Generics and volume. Generic drugs account for nine out of ten U.S. prescriptions [28], making them central to overall volume even as they contribute a smaller share of spending.
• Coverage and price. Insurance design, government programs (Medicare, Medicaid), and net pricing determine how much of underlying medical need converts into paid volume.

Demand is broadly non-cyclical — people take needed medicines in good times and bad — which is why the sector is considered defensive.

---

7. Regulation

Pharmaceuticals are among the most heavily regulated products in the economy. The load-bearing pieces:

• FDA approval. The Food and Drug Administration must approve a new drug (via a New Drug Application, or NDA) as safe and effective before it can be sold, and it inspects manufacturing plants for quality. Approval is the gate the entire business model depends on.
• Hatch-Waxman Act (1984). This law built the modern generics system: it lets a generic maker win approval through an Abbreviated New Drug Application (ANDA) by proving its copy is bioequivalent to the brand, without repeating full clinical trials — while giving brands patent-term restoration and exclusivity windows in return [29]. It is why cheap generics exist and why patent-expiration timing matters so much.
• BPCIA (2009). The Biologics Price Competition and Innovation Act created a parallel pathway (the "351(k)" route) for biosimilars — near-copies of biologic drugs — with a 12-year exclusivity period for the original biologic and a structured patent-exchange process [29].
• Inflation Reduction Act (IRA, 2022) — Medicare price negotiation. For the first time, Medicare (run by CMS, the Centers for Medicare & Medicaid Services) can negotiate prices on its most expensive drugs. The first 10 negotiated prices take effect January 2026, at a minimum 38% below the 2023 list price; CMS estimated that applying negotiated prices to 2023 utilization would have reduced net spending on the selected drugs by $6 billion, or 22% [30]. The program expands to more drugs each year and is a structural headwind to branded pricing.
• Tariffs and supply-chain policy. Under a Section 232 (national-security) trade action, the administration issued an April 2026 proclamation planning tariffs up to 100% on certain patented pharmaceutical products and ingredients, phasing in through mid-to-late 2026 [31]. This is aimed at pulling manufacturing back onshore (see Section 9).
• PBMs and pricing scrutiny. Pharmacy benefit managers, drug-pricing transparency, and rebate practices are under active political and regulatory pressure, which affects how much of the list price reaches the manufacturer.

---

8. Competitive dynamics and consolidation

Competition in this industry is a race against the patent clock. Because every blockbuster eventually loses exclusivity, a drugmaker must continually refill its pipeline or shrink. This produces a distinctive dynamic:

• The 2026–2030 patent cliff. An unusually large wave of patents is expiring. The U.S. market is projected to lose over $230 billion in revenue between 2025 and 2030 across roughly 190 drugs, about 69 of them blockbusters [32] — including Merck's Keytruda, the world's best-selling drug, around 2028 [32].
• M&A as pipeline insurance. Facing the cliff, large firms buy smaller ones to acquire new drugs. 2025 pharma M&A reached about $240 billion in deal value, up 81% year over year — the strongest deal year since 2019 [33]. Big Pharma increasingly functions as a commercialization-and-distribution machine that buys innovation from smaller biotechs.
• Biosimilar and generic erosion. As biologics lose protection, biosimilar competition (still less aggressive than small-molecule generics, but growing) eats into the highest-value franchises. Generic makers are moving up into biosimilars and complex generics to escape commodity pricing [18].
• Consolidation in generics and manufacturing. The generic and contract-manufacturing tiers have been consolidating for years — thin margins reward scale, and the private-equity-backed take-private of large CDMO Catalent (2024) is emblematic [19].

---

9. Risks

• Patent expiration (LOE). The defining risk: a top drug's revenue can fall 80–90% within a year of generic entry [32]. Companies overexposed to a single aging blockbuster are the most vulnerable.
• Pipeline failure. Most drug candidates fail in trials. A single failed late-stage study can wipe out much of a clinical-stage company's value overnight — the core risk in biotech investing.
• Pricing and policy pressure. IRA negotiation, expanding each year, plus PBM reform and general political hostility to drug prices, structurally compress branded pricing power [30][31].
• Tariffs and supply-chain fragility. The U.S. is deeply dependent on imported ingredients: U.S. pharmaceutical imports jumped from $73 billion (2014) to $215 billion (2024) [34]. FDA reports that, as of 2025, approximately 53% of branded finished drugs and 69% of generic finished drugs distributed in the United States were manufactured abroad, and only 11% of API manufacturers were U.S.-based [35]. Over half of active pharmaceutical ingredients come from India and the EU [36], and India in turn sources much of its raw material from China [36]. New tariffs [31] raise costs and could disrupt supply, especially for thin-margin generics; in response manufacturers have pledged nearly $283 billion in new U.S. plants since the 2025 trade action opened [34]. Whether reshoring actually reaches the low-margin generic base is uncertain.
• Manufacturing quality and shortages. FDA plant failures cause recalls and drug shortages. FDA states that manufacturing quality problems are the most common reason for drug shortages; other causes include production delays, raw-material constraints, unexpected demand, and discontinuations [37]. Older sterile injectables are particularly vulnerable because relatively few lines can make them and the processes have long lead times.
• Regulatory and inspection risk. An adverse inspection, contamination event, data-integrity failure, or inadequate validation can halt production, trigger recalls, or delay approval. FDA reported 9,850 domestic and 4,839 foreign registered drug establishments at September 30, 2024 [38]. GAO has designated FDA oversight of the global pharmaceutical supply chain a persistent high-risk issue and notes the difficulty of inspecting foreign plants [39].
• Litigation. Product-liability, patent, and opioid-type litigation can create multibillion-dollar liabilities.
• Labor and skills. Facilities need experienced quality-assurance personnel, validation engineers, microbiologists, chemists, automation specialists, and operators trained on specific equipment and procedures. Losing qualified staff can impair compliance or delay line qualification.
• Concentration risk for investors. Because value is so concentrated in individual drugs, single-stock outcomes are unusually binary.

---

10. How to invest and the outlook

Public-market routes.

• Mature branded drugmakers (e.g., JNJ, MRK, ABBV, AZN, NVS) — profitable, dividend-paying, defensive; the risk is drug-specific, not economic. Screen for pipeline strength and patent-cliff exposure.
• Growth leaders (e.g., LLY, NVO) — driven by the obesity/GLP-1 boom; higher valuations and higher expectations.
• Generics and CDMOs (e.g., TEVA, VTRS, TMO) — value/turnaround profiles tied to volume, cost, and consolidation, not blockbuster upside.
• Diversified exposure — sector funds and ETFs (exchange-traded funds) spread single-drug risk across many names; biotech funds add higher-risk, clinical-stage exposure without betting on one company.

Private-market routes.

• Venture capital in clinical-stage biotech — the highest-risk, highest-reward layer, monetized through acquisition or IPO.
• Private equity in generics, specialty manufacturers, and CDMOs — cash-flow and consolidation plays (the model behind the Catalent take-private).
• Drug-royalty investing — buying a share of an approved drug's future sales for upfront capital, a lower-volatility way to own pharmaceutical cash flows.

Private-market underwriting. Underwriting should focus on customer and molecule concentration, quality history, regulatory status, capacity utilization, backlog cancellation rights, maintenance capital, environmental liabilities, and the cost and time required to transfer a product to another site. Private ownership does not remove product risk: a CDMO can lose a major program after a failed trial, while a captive plant can become stranded after a patent expiry or portfolio sale.

Near-term drivers to watch (forward-looking).

• The 2026–2030 patent cliff [32] will separate companies that refilled their pipelines from those that didn't, and should keep M&A elevated [33].
• IRA price negotiation takes real effect in 2026 and widens each year — a persistent margin headwind for branded sellers [30].
• Tariffs and reshoring [31][34] will reshape where drugs are made and could pressure generic supply and prices even as branded firms build U.S. capacity.
• The obesity/GLP-1 franchise remains the dominant growth story, with competition, pricing, and manufacturing scale-up as the key swing factors [1][17].

The reasonable expectation is steady overall volume growth (aging demand is durable and largely recession-proof), narrowing branded pricing power under policy pressure, an intense scramble to replace expiring blockbusters, and a gradual — but incomplete — shift of manufacturing back toward the United States.

A measurement note. NAICS 325412 is not synonymous with "the pharmaceutical industry" or a measure of U.S. drug spending. It is a domestic establishment classification centered on finished non-biological preparations. It excludes much biologic and API production, includes products such as veterinary drugs and in-vivo diagnostics, and does not capture imported finished drugs except to the extent that a U.S. establishment performs qualifying manufacturing. Corporate pharmaceutical revenue, CMS drug spending, and Census domestic shipments answer different questions and should not be added together or substituted for one another.

---

Sources

1. PharmExec (MJH Life Sciences), "GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports," 2025. https://www.pharmexec.com/view/glp-1-surge-fuels-10-2-rise-us-prescription-drug-spending-2024
2. Centers for Medicare & Medicaid Services, "National Health Expenditure Fact Sheet (retail prescription drug spending and projections)," 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
3. NAICS Association, "NAICS Code 325412 — Pharmaceutical Preparation Manufacturing (2022 definition and exclusions)," 2022. https://www.naics.com/naics-code-description/?code=325412
4. U.S. Census Bureau, "2022 NAICS Definition — 325412," 2022. https://www.census.gov/naics/?details=325412&input=325412&year=2022
5. U.S. Food and Drug Administration, "Current Good Manufacturing Practice (CGMP) Regulations," 2025. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
6. U.S. Food and Drug Administration, "Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry," 2016. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry
7. U.S. Food and Drug Administration, "Advancing Product Quality (emerging technology program)," 2025. https://www.fda.gov/drugs/pharmaceutical-quality-resources/advancing-product-quality
8. U.S. Census Bureau, County Business Patterns (CBP), NAICS 325412, 2023. https://www.census.gov/programs-surveys/cbp.html
9. U.S. Census Bureau, 2022 Economic Census — Concentration and receipts, NAICS 325412, 2022. https://www.census.gov/programs-surveys/economic-census.html
10. U.S. Census Bureau, Annual Integrated Economic Survey (AIES), Table AIES31BASIC01, NAICS 325412, 2023. https://data.census.gov/table/AIESBASICTIMESERIES.AIES31BASIC01?q=325412
11. U.S. Census Bureau, Annual Integrated Economic Survey (AIES), Table AIES31INV (inventories), NAICS 325412, 2023. https://data.census.gov/table/AIESMISCSECTORTIMESERIES.AIES31INV?q=325412
12. U.S. Small Business Administration, "Table of Small Business Size Standards," 2023. https://www.sba.gov/document/support-table-size-standards
13. PhRMA / TEConomy Partners, "The Economic Impact of the U.S. Biopharmaceutical Industry (2024 report; ~$96B R&D in 2023, >1M direct jobs)," 2024. https://phrma.org/resources/industry-economic-impact
14. Fierce Pharma, "The top 20 pharma companies by 2025 revenue," 2026. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2025-revenue
15. Bullfincher, "Johnson & Johnson Revenue Breakdown by Segment (Innovative Medicine $60.4B, FY2025)," 2026. https://bullfincher.io/companies/johnson-johnson/revenue-by-segment
16. BioSpace, "J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales," 2026. https://www.biospace.com/business/j-j-reigns-as-top-pharma-by-revenue-while-lilly-leapfrogs-on-strong-obesity-sales
17. Fierce Pharma, "Novo Nordisk predicts milder sales growth in 2025 after obesity star Wegovy doubles sales in Q4," 2026. https://www.fiercepharma.com/pharma/novo-nordisk-predicts-milder-sales-growth-2025-after-obesity-star-wegovy-doubles-numbers-q4
18. DrugPatentWatch, "Generic Drug Partnerships: Biosimilars, CDMOs, and the Patent Cliff," 2025. https://www.drugpatentwatch.com/blog/the-future-of-partnerships-in-generic-drug-development/
19. Catalent, "Novo Holdings Completes Acquisition of Catalent," 2024. https://www.catalent.com/catalent-news/novo-holdings-completes-acquisition-of-catalent/
20. PCI Pharma Services, "Strategic Investment by Bain Capital, Kohlberg and Mubadala," 2025. https://pci.com/news/strategic-investment-bain-capital-kohlberg-and-mubadala
21. State Street Global Advisors, "SPDR S&P Pharmaceuticals ETF (XPH)," 2025. https://www.ssga.com/us/en/intermediary/etfs/state-street-spdr-sp-pharmaceuticals-etf-xph
22. Eli Lilly and Company, Form 10-K (FY2025), U.S. SEC, 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
23. U.S. Food and Drug Administration, "Generic Drug Facts," 2025. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
24. Teva Pharmaceutical Industries, Form 8-K (Q1 2026 results; 49.5% gross margin), U.S. SEC, 2026. https://www.sec.gov/Archives/edgar/data/0000818686/000117184326002796/exh_991.htm
25. Viatris Inc., Form 10-K (FY2025; 35% gross margin), U.S. SEC, 2026. https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm
26. U.S. Census Bureau, "2023 Population Projections (65+ to surpass under-18 in 2029)," 2023. https://www.census.gov/newsroom/press-releases/2023/population-projections.html
27. IQVIA Institute, "The Use of Medicines in the U.S. — Usage and Spending Trends and Outlook," 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024
28. U.S. Food and Drug Administration, "Generic Drugs — Buying Using Medicine Safely," 2025. https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs
29. UC Berkeley Law (BCLT), "Hatch-Waxman and the BPCIA: How Two Statutes Govern the Drug and Biologic Patent Lifecycle," 2024. https://www.law.berkeley.edu/research/bclt/bclt-legal-analysis/start-up-s7/
30. Centers for Medicare & Medicaid Services (CMS), "Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026," 2025. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
31. Mintz, "Inflation Reduction Act Update: What's Changing in Drug Pricing (incl. Section 232 pharmaceutical tariffs)," 2026. https://www.mintz.com/insights-center/viewpoints/2026-06-22-inflation-reduction-act-update-whats-changing-drug-pricing
32. Drug Discovery News, "Blockbuster drugs face a massive patent cliff in 2026," 2025. https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019
33. BS Capital Markets, "Patent Cliffs and the New Pharma M&A Cycle (2025 M&A ~$240B, +81% YoY)," 2026. https://www.bscapitalmarkets.com/patent-cliffs-and-the-new-pharma-ma-cycle.html
34. Coalition for a Prosperous America, "Skyrocketing Pharmaceutical Imports to the U.S. (imports $73B→$215B; ~$283B reshoring pledges)," 2025. https://prosperousamerica.org/skyrocketing-pharmaceutical-imports-to-the-u-s-endanger-national-security/
35. U.S. Food and Drug Administration, "FDA Manufacturing PreCheck Pilot Program (53% branded / 69% generic finished drugs manufactured abroad; 11% API manufacturers US-based)," 2025. https://www.fda.gov/industry/fda-manufacturing-precheck-pilot-program
36. U.S. Pharmacopeia, "Over half of the active pharmaceutical ingredients (API) for U.S. prescription medicines come from India and the EU," 2025. https://qualitymatters.usp.org/over-half-active-pharmaceutical-ingredients-api-prescription-medicines-us-come-india-and-european
37. U.S. Food and Drug Administration, "Drug Shortage FAQ (manufacturing quality as most common cause)," 2025. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
38. U.S. Food and Drug Administration, "FY2024 Drug Establishment Inspection Report (9,850 domestic / 4,839 foreign registered establishments)," 2024. https://www.fda.gov/media/187960/download
39. U.S. Government Accountability Office, "GAO-24-107359: FDA Oversight of Global Pharmaceutical Supply Chain," 2024. https://www.gao.gov/products/gao-24-107359